View all AJHO CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.



Accreditation/ Credit Designation


CDK4/6 Inhibitors in Breast Cancer

Release Date: March 1, 2017
Expiration Date: March 1, 2018
Media: Print with online posttest, evaluation, and request for credit

Overview

This activity is designed to inform physicians about the rationale for use and recent data on the utility of CDK4/6 inhibitors in the treatment of breast cancer.

Instructions for Participation/How to Receive Credit:

  1. Read the article in its entirety.
  2. Use the QR code or type into your Web browser to access the posttest.
  3. Complete and pass the posttest with a score of 70% or higher.
  4. Complete the evaluation and request for credit.

Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists involved in the care of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the management of breast cancer are also invited to participate.

Learning Objectives

After participating in this CME/CE activity, learners should be better prepared to:

  • Explain the biological and clinical rationale supporting the role of CDK4/6 inhibition in the treatment of breast cancer
  • Discuss recent outcomes and efficacy data for approved and emerging CDK4/6 inhibitory therapies in the treatment of advanced or metastatic breast cancer
  • Review safety and toxicity data from clinical trials for approved and emerging CDK4/6 inhibitory therapies

The American Journal of Hematology/ Oncology® Editorial Board

Debu Tripathy, MD
Professor and Chairman
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosure: Grant/research support from Genentech/Roche, Pfizer, Puma Biotechnology Inc, and Novartis (clinical trial support contracted to the University of Southern California and MD Anderson Cancer Center); consultant for Eisai, OncoPlex Diagnostics, Merck, and Novartis.

Faculty

Richard S. Finn, MD
Ronald Reagan UCLA Medical Center
Disclosure: Disclosure: Consultant: Pfizer, Bayer, Novartis, Bristol-Myers Squibb

 



Staff/Planner Disclosures and Conflict of Interest Resolution

The staff of Physicians’ Education Resource®, LLC (PER®), and the editorial staff of The American Journal of Hematology/Oncology® have no relevant financial relationships with commercial interests to disclose.

It is the policy of PER® to ensure fair balance, independence, objectivity, and scientific objectivity in all of our CME/CE activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 1.0 Contact Hour.

This activity is funded by PER®

Off-Label Disclosure and Disclaimer

This continuing medical and nursing education activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, and management options for a specific patient’s medical condition.

Disclaimer

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC.

Contact information for questions about the activity:
Physicians’ Education Resource®, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
Phone: (888) 949-0045
E-mail: info@gotoper.com





Calendar of Events
SUNMONTUESWEDTHURSFRISAT
 123456
78910111213
14151617181920
21222324252627
28293031
Filter By